Skip to content

Home
Insights
Brochures
Careers
About us
News

Home
Insights
Brochures
Careers
About us
News

Uncategorized

Highlights from the Week of 21st September 2026 - 28th September 2026 ( FDA, Approval ) Mirum obtains FDA approval for ATEBRIOZ tablets to reduce the volume of HO in those aged 12 years and older with FOP ( FDA, Approval ) Lantheus gets final approval from FDA for BRAVNETSA to treat adults with somatostatin receptor-positive GEP-NETs, including foregut, midgut, and hindgut neuroendocrine tumors ( FDA, Approval ) Eli Lilly gains FDA approval for ONSWIK, indicated along with diet and exercise, to control high blood sugar in adults with type 2 diabetes ( FDA, Approval ) FDA grants approval to Elevar Therapeutics' LYRFIGTU as a treatment option for CCA with FGFR2 fusion or other rearrangement Pg 1/5 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 21st Sep – 28th Sep in the world of pharma and healthcare!

Uncategorized / YASHASWINI N

Highlights from the Week of 21st Sep – 28th Sep in the world of pharma and healthcare! Read More »

2026 RBC Capital Markets Global Healthcare Conference Bank of America Global Healthcare Conference Sep 22,2026 To Sep 23,2026 Sep 23 Sep 22 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of Sep 22,2026 To Sep 23,2026

Uncategorized / YASHASWINI N

Attention stay up to date with the latest investor calls by checking out our calendar for the week of Sep 22,2026 To Sep 23,2026 Read More »

Highlights from the week of 14th Sep - 21st Sep Alfasigma ( CHMP, Positive Opinion ) CHMP issues positive opinion for Alfasigma's filgotinib to treat axSpA in patients with an inadequate response to conventional therapy Novo Nordisk ( CHMP, Positive Opinion ) Novo Nordisk gets positive CHMP opinion for SOGROYA, administered once weekly, for children with ISS and persistent growth disturbances AstraZeneca ( CHMP, Positive Opinion ) CHMP recommends positive opinion to AstraZeneca's ENHERTU as a monotherapy for the adjuvant treatment of adults with resected HER2-positive breast cancer Roche ( CHMP, Positive Opinion ) Roche gains a positive CHMP opinion for its OCREVUS IV infusion to treat patients aged 10 years and older with RMS All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 14th Sep – 21st Sep in the world of pharma and healthcare!

Uncategorized / YASHASWINI N

Highlights from the Week of 14th Sep – 21st Sep in the world of pharma and healthcare! Read More »

2026 RBC Capital Markets Global Healthcare Conference Morgan Stanley 24th Annual Global Healthcare Conference Sep 14,2026 To Sep 15,2026 Sep 15 Sep 14 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of September 14,2026 To September 15,2026

Uncategorized / YASHASWINI N

Attention stay up to date with the latest investor calls by checking out our calendar for the week of September 14,2026 To September 15,2026 Read More »

Highlights from the Week of 07th September 2026 - 14th September 2026 ( FDA, Accelerated Approval ) FDA provides accelerated approval to Bayer's sevabertinib to treat locally advanced or metastatic NSCLC with HER2/ERBB2 tumors ( FDA, Priority Review ) FDA accepts Takeda's TAK-279 under Priority Review to treat adults with moderate-to-severe plaque psoriasis ( FDA, Priority Review ) Genentech receives Priority Review from FDA for its sBLA, ENSPRYNG to treat MOGAD ( FDA, Fast Track ) Sobi obtains Fast Track designation from FDA for pacritinib to treat VEXAS syndrome Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 07th September – 14th September in the world of pharma and healthcare!

Uncategorized / YASHASWINI N

Highlights from the Week of 07th September – 14th September in the world of pharma and healthcare! Read More »

2026 RBC Capital Markets Global Healthcare Conference Wells Fargo 21st Annual Healthcare Conference Sep 09,2026 To Sep 10,2026 Sep 10 Sep 09 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of September 09,2026 To September 10,2026

Uncategorized / YASHASWINI N

Attention stay up to date with the latest investor calls by checking out our calendar for the week of September 09,2026 To September 10,2026 Read More »

Highlights from the week of 31st Aug - 07th Sep PharmaEssentia ( FDA, Approval ) FDA approves PharmaEssentia's BESREMi to treat adults with Essential Thrombocythemia, regardless of genotype or disease status Ionis ( FDA, Approval ) Ionis' ZANVASTRO gets FDA approval to treat Alexander disease in pediatric and adults patients AstraZeneca ( FDA, Approval ) FDA provides approval to AstraZeneca's ETCAMAH, in combination with CDK 4/6 inhibitor, to treat adults with HR-positive, HER2- negative, locally advanced or metastatic breast cancer AstraZeneca ( EU, Approval ) AstraZeneca's ENHERTU, in combination with pertuzumab, gets EU approval to treat adults with unresectable or metastatic HER2-positive breast cancer All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 31st August – 07th September in the world of pharma and healthcare!

Uncategorized / YASHASWINI N

Highlights from the Week of 31st August – 07th September in the world of pharma and healthcare! Read More »

September is Prostate Cancer Awareness cancer remains one of the most common cancers affecting men worldwide; however, when detected early, it is highly treatable. Raising awareness around timely screening, emerging diagnostic tools, and evolving therapeutics is critical to improving clinical outcomes.

Uncategorized / Nayana NK

September is Prostate Cancer Awareness cancer remains one of the most common cancers affecting men worldwide; however, when detected early, it is highly treatable. Raising awareness around timely screening, emerging diagnostic tools, and evolving therapeutics is critical to improving clinical outcomes. Read More »

Highlights from the Week of 24th August 2026 - 31st August 2026 ( US, Launch ) Cycle Pharma launches CAVHANZA in the US to offer dosing flexibility and tolerability for patients with Ph+ CML ( EU, Launch ) Celltrion launches OMLYCLO 300 mg PFS and AI presentations in key European markets for CSU and allergic asthma ( FDA, Approval ) J&J receives approval from the FDA for IMAAVY to treat wAIHA in patients aged 12 and older ( FDA, Approval ) Jazz Pharmaceuticals gets FDA approval for ZIIHERA regimens to treat adults with unresectable locally advanced or metastatic HER2+ gastroesophageal adenocarcinoma Pg 1/5 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 24th August – 31st August in the world of pharma and healthcare!

Uncategorized / YASHASWINI N

Highlights from the Week of 24th August – 31st August in the world of pharma and healthcare! Read More »

Highlights from the week of 17th Aug - 24th Aug Biocon ( FDA, Approval ) Biocon receives approval from FDA for YESINTEK 45 mg/0.5 mL and 90 mg/mL single-dose prefilled autoinjectors to treat adult and pediatrics with psoriasis, and adults with CD and UC Regeneron ( FDA, Approval ) Regeneron gets FDA approval for PASATRU, indicated to reduce the formation of new HO lesions and clinician-assessed flare-ups in adults with FOP Ultragenyx ( FDA, Accelerated Approval ) FDA grants accelerated approval for Ultragenyx's DTX401, indicated to treat GSDIa in adults and pediatrics Johnson&Johnson ( EU, Approval ) J&J receives indication extension approval from EC for TECVAYLI in combination with daratumumab to treat adults with RRMM who received at least one prior therapy All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 17th August – 24th August in the world of pharma and healthcare!

Uncategorized / YASHASWINI N

Highlights from the Week of 17th August – 24th August in the world of pharma and healthcare! Read More »

1 2 … 17 Next →

Search

Recent Posts

Highlights from the Week of 21st Sep – 28th Sep in the world of pharma and healthcare!
Attention stay up to date with the latest investor calls by checking out our calendar for the week of Sep 22,2026 To Sep 23,2026
Highlights from the Week of 14th Sep – 21st Sep in the world of pharma and healthcare!
Attention stay up to date with the latest investor calls by checking out our calendar for the week of September 14,2026 To September 15,2026
Highlights from the Week of 07th September – 14th September in the world of pharma and healthcare!

Recent Comments

No comments to show.

Archives

September 2026
August 2026
July 2026
June 2026
May 2026
April 2026
March 2026
February 2026
January 2026
December 2025
November 2025
October 2025
September 2025
August 2025
July 2025
June 2025
May 2025
April 2025
March 2025
February 2025
January 2025

Categories

Uncategorized

The Pharma BI division of

Vyuhgenics Inc.

Henderson, Nevada, USA – 89014

Vyuhpharma ®, All Rights Reserved.

Sitemap

Terms of Use

Privacy Policy

Connect with us

Please fill in the information below, and we'll get back to you.

Full Name

Email Address

Your Company

Contact

Your message